Skip to main content
SpringerLink
Log in

Prognostic Factors and Treatment of Multiple Myeloma: Interest of a Cyclic Sequential Chemohormonotherapy Combining Cyclophosphamide, Melphalan, and Prednisone

  • Chapter
Book cover Lymphoid Neoplasias II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 65))

Abstract

In 1889, Kalher succeeded in establishing the relationship between Bence Jones proteinuria [27], discovered in 1845, and the bone “tumor,” called “multiple myeloma” by Rustisky in 1873 [51]. Later, in 1900, Wright identified the plasmocytic nature of the tumoral proliferation. More recently, after Grabar’s discovery of immunoelectrophoresis procedures in 1953, several authors documented the immunologic significance of the disease [12, 22, 32, 39, 48]. It is now well-established that Kahler’s disease is restricted to monoclonal primary plasmocyte tumor proliferations, usually associated with early dissemination of tumor cells in bone marrow and excretion, by these cells, of monoclonal immunologic products in the serum and urine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alberts, D. S., Salmon, S. E. : Adriamycin (NSC-12127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother. Rep. 59, 345–350 (1975)

    PubMed  CAS  Google Scholar 

  2. Alberts, D. S., Durie, B. G. M., Salmon, S. E. : Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse. Lancet 1976 I, 926–928

    Article  Google Scholar 

  3. Alexanian, R., Bergsagel, D., Migliore, P., Vaughan, W., Howe, C. D. : Melphalan therapy for plasma cell myeloma. Blood 31,1 (1968)

    PubMed  CAS  Google Scholar 

  4. Alexanian, R., Haut, A., Khan, A. V., Lane, M., McKelvey, E. M., Migliore, P. J., Stuckey, W. J., Wilson, H. E. : Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. J.A.M.A. 208, 1680–1685 (1969)

    Article  PubMed  CAS  Google Scholar 

  5. Alexanian, R., Balarzak, S., Boneet, J. D., Gehan, E. A., Haut, A., Hewlett, J. S., Monto, R. W. : Prognostic factors in multiple myeloma. Cancer 36, 1192–1201 (1975)

    Article  PubMed  CAS  Google Scholar 

  6. Azam, L., Delamore, I. W. : Combination therapy for myelomatosis. Br. Med J. 1974, IV,560–564

    Article  Google Scholar 

  7. Bergsagel, D. E.: Evaluation of new chemotherapeutic agent in the treatment of multiple myeloma. IV. Phenylalanine mustard (NSC 8806). Cancer Chemother. Rep. 21, 87–99 (1962)

    PubMed  CAS  Google Scholar 

  8. Bergsagel, D. E.: Myeloma proteins and the clinical response to melphalan therapy. Science 148, 367–377 (1965)

    Article  Google Scholar 

  9. Bernard, J., Seligmann, M., Danon, F.: Essai de traitement de 21 malades atteints de myelome ou de macroglobulinémie par le pdi 2 chloréthylaminolphenyl alanine (Melphalan). Nouv. Rev. Fr. Hematol. 2, 611–616 (1962)

    PubMed  CAS  Google Scholar 

  10. Bontoux, D., Chenebit, D., Delbarre, F.: Essai détude comparative du melphalan et de la cyclophosphamide dans le traitement de la maladie de Kahler. Rev. Rhum. 37, 817–824 (1970)

    PubMed  CAS  Google Scholar 

  11. Brock, N., Hohorst, A. J. : Metabolism of cyclophosphamide. Cancer 20, 900–904 (1967)

    Article  PubMed  CAS  Google Scholar 

  12. Caggiano, V., Cuttner, J., Salomon, A.: Myeloma proteins. Bence Jones proteins and normal immunoglobulins in multiple myeloma. Blood 30, 265–287 (1967)

    PubMed  CAS  Google Scholar 

  13. Carbone, P. P., Kellerhouse, L. E., Gehan, E. A. : Plasmocytic myeloma: a study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am. J. Med.42, 937–949

    Google Scholar 

  14. Chavaz, A., Mignon, F., Kanfer, A., Richet, G.: Traitement de l’insuffisance rénale du myelome multiple par l’hémodialyse chronique. A propos de 4 cas. Nouv. Presse Med. 5, 565–569 (1975)

    Google Scholar 

  15. Costa, G.: An assessment of L phenylalanine mustard in human multiple myeloma. Proc. Am. Assoc. Cancer Res. 4, 12 (1963)

    Google Scholar 

  16. Costa, G., Engle, R. L., Schilling, A., Carbonne, P., Kochwa, S., Prognostic, R. L., Glidewell, O.: Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am. J. Med. 54, 589–599 (1973)

    Article  Google Scholar 

  17. Delbarre, F., Siguier, F., Godeau, P., Saporta, L., Seligman, M., Hurez, D.: La maladie de Kahler à plasmocytes non excrétants. Ann. Med. Interne. (Paris) 121, 537–544 (1970)

    CAS  Google Scholar 

  18. De Vita, V. T., Schein, P. S. : The use of drugs in combination for the treatment of cancer: rationale and results. N. Engl. J. Med. 288, 998 (1973)

    Article  Google Scholar 

  19. Drewinko, M., Brown, B. W., Humphrey, R., Alexanian, R.: effect of chemotherapy on the labelling index of myeloma cells. Cancer 34, 526 (1974)

    Article  PubMed  CAS  Google Scholar 

  20. Drivsholm, A., Videback, A.: Alkeran (melphalan) in the treatment of myelomatosis. Acta Med. Scand. 179.(Suppl. 445), 187–193 (1966)

    Google Scholar 

  21. Durie, G. M., Salmon, S. E. : A clinical staging for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features. Response to treatment and survival. Cancer 36, 842–854(1975)

    Article  PubMed  CAS  Google Scholar 

  22. Fahey, J. L., Scoggins, R. S., Utz, J. P., Szwed, C.: Infection, antibody response and gammaglobulin components in multiple myeloma and macroglobulinemia. Amer. J. Med. 35, 698–707 (1963)

    Article  PubMed  CAS  Google Scholar 

  23. Feinleib, M., Macmahon, B.: Duration or survival in multiple myeloma. J.N.C.I. 24, 1259–1269 (1960)

    Google Scholar 

  24. George, R. P., Poth, J. L., Gordon, D., Schrier, S. L. : Multiple myeloma intermittent combination chemotherapy compared to continuous therapy. Cancer 29, 1665–1670 (1972)

    Article  PubMed  CAS  Google Scholar 

  25. Hoogstraten, B., Costa, J.: Intermittent melphalan therapy in multiple myeloma. J.A.M.A. 209, 251–253 (1967)

    Article  Google Scholar 

  26. Jones, H. B.: On a new substance occurring in the urine of a patient with urollitics ossium. Philos, Trans. R. Soc. Lond. (Biol. Sci.) 55–62 (1848)

    Google Scholar 

  27. Kahler, O.: Zur Symptomatologik des multiplen Myeloms: Beobachtung von Albumosurie. Prag. Med. (Wochenscht.) 14, 33–35 (1889)

    Google Scholar 

  28. Korst, D. R., Wilson, H. E., Fowler, W. M., Will, J. R., Clifford, G. O., Louis, J.. Treatment of multiple myeloma. An analysis of cyclophosphamide (Cytoxan) therapy in 170 patients. J. LAb. Clin. Med. 62 990(1963)

    Google Scholar 

  29. Korst, D. R., Clifford, G. O., Fowler, W. M., Louis, J., Will, J., Wilson, H. E. : Multiple myeloma. II. Analysis of cyclophosphamide therapy in 165 Patients. J.A.M.A. 189, 758–762 (1964)

    Article  PubMed  CAS  Google Scholar 

  30. Lee, B. J., Sahakian, G., Clarkson, B. D., Krakoff, I. H. : Combination chemotherapy of multiple myeloma with alkeran, Cytoxan, vincristine, prednisone and BCNU. Cancer 33, 533–538 (1974)

    Article  PubMed  CAS  Google Scholar 

  31. Lee, S. H., Polesky, H. F., Shapiro, F. L. : Chronic hemodialysis in myelomatosis. Ann. Intern. Med. 77, 239–242(1972)

    Google Scholar 

  32. Mannik, M., Kunkel, H. G. : Classification of myeloma proteins, Bence Jones proteins and macroglobulins into two groups on the basis of common antigenic characters. J. Exp. Med. 116, 859- 877 (1962)

    Article  PubMed  CAS  Google Scholar 

  33. Mavligit, G. M., Gutterman, J. U., Hersh, E. M., Alexanian, R.: Cell mediated immunity to plasma cell myeloma: specific inhibition by a serum factor adhering to effector lymphocytes (38382). Proc. Soc. Exp. Biol. Med. 147, 537–540 (1974)

    PubMed  CAS  Google Scholar 

  34. McArthur, J. R., Athens, J. W., Wintrob, M. M., Cartwright, G. E. : Melphalan and myeloma. Experience with a low-dose continuous regimen. Ann. Intern. Med. 72, 665–670 (1970)

    PubMed  CAS  Google Scholar 

  35. Medical Research Council, London WIN 4AL: Report of the medical research council’s working party for therapeutic trials in leukemia. Myelomatosis: comparison of melphalan and cyclophosphamide therapy. Br. Med. J. 1971 I, 640–641

    Google Scholar 

  36. Meshak, G., Seligman, M., Jacquillat, C., Basch, A., Bernard, J.: Le traitement du myelome multiple par le melphalan. Presse Med. 75, 2301–2306 (1967)

    Google Scholar 

  37. Nauts, H. C.: Multiple Myeloma: Beneficial Effects of Acute Infectious or Immunotherapy (Bacterial Vaccines). Monograph 13. New York: Cancer Research Institute Inc. 1975

    Google Scholar 

  38. Osgood, E. E.: The survival time of patients with plasmocytic myeloma. Cancer Chemother. Rep. 9, 1–10 (1960)

    PubMed  CAS  Google Scholar 

  39. Paraskevas, F., Heremans, J., Waldenstrom, J.: Cytology and electrophoretic pattern in yla 052a) myeloma. Acta Med. Scand. 170, 575–589 (1961)

    Article  PubMed  CAS  Google Scholar 

  40. Rivers, S. L., Patno, M.E.: Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. J.A.M.A. 207, 1328–1334 (1969)

    Article  PubMed  CAS  Google Scholar 

  41. Rivers, S. L., Whittington, R. M., Patno, M. E. : Cyclophosphamide in treatment of multiple myeloma. Cancer Chemother. Rep. 29, 115–119 (1963)

    PubMed  CAS  Google Scholar 

  42. Rivers, S. L., Whittington, R. M., Patno, M. E. : Comparison of effect of cyclophosphamide and a placebo in treatment of multiple myeloma. Cancer Chemother. Rep. 29, 115–119 (1963)

    PubMed  CAS  Google Scholar 

  43. Saporta, L., Hugon, C., Rondier, J., Bontoux, D., Delbarre, F.: Pronostic de la maladie de Kalher chez des patients traités ou non par les agents alkylants (à propos de 45 cas), rev. Rhum. 39, 11–18 (1972)

    CAS  Google Scholar 

  44. Salmon, S. E.: Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 45, 119–129(1975)

    PubMed  CAS  Google Scholar 

  45. Salmon, S. E., Smith, B. A. : Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J. Clin. Invest. 49, 1114–1121 (1970)

    Article  PubMed  CAS  Google Scholar 

  46. Salmon, S. E., Smith, B. A. : Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. J. Immunol. 104, 665 (1970)

    PubMed  CAS  Google Scholar 

  47. Salmon, S. E., Smith, B. A. : Induction of tumor susceptibility to cycle active agents in IgG multiple myeloma. Clin. Res. 20, 570 (1972)

    Google Scholar 

  48. Salomon, A., Fahey, J. L., Malmgren, R. A. : Immunohistologic localization of gamma 1 macroglobulins Beta 2A myeloma proteins 6.6S gamma-myeloma proteins and Bence-Jones protein. Blood 21, 403–423 (1963)

    Google Scholar 

  49. Speed, D. E., Galton, D. A. G., Swan, A.: Melphalan in the treatment of myelomatosis. Br. Med. J. 1964 I, 1664

    Google Scholar 

  50. Sullivan, P. W., Salmon, S. E. : Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51, 1697–1708 (1972)

    Article  PubMed  CAS  Google Scholar 

  51. Rustizky, J. von: Multiple myelom. Dtsch. Chir. 3, 162–172 (1873)

    Article  Google Scholar 

  52. Waldenstrom, J.: Melphalan therapy in myelomatosis. Br. Med. J. 1964 I, 859–865

    Article  Google Scholar 

  53. Wheller, G. P.: Studies related to mechanisms of resistance to biological alkylating agents. Cancer Res. 23, 1334(1963)

    Google Scholar 

  54. Zinneman, H. H., Hall, W. H. : Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann. Intern. Med. 41, 1152–1163 (1954)

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. Belpomme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Pouillart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Amor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Feuilhade De Chauvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Belpomme
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Menkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Delrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Depierre
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B. Le Mevel
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Serrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Fries
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. F. Delbarre
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G. Mathé
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut de Cancérologie et d’Immunogénétique, Hôpital Paul-Brousse, 14-16, Avenue Paul-Vaillant-Couturier, F-94800, Villejuif, France

    Georges Mathé

  2. Laboratory of Immunochemistry and Immunopathology INSERM (U 108), and Laboratory of Cytology Research Institute on Blood Diseases, Hôpital Saint-Louis, 2, Place du Docteur-A. Fournier, F-75010, Paris, France

    Maxime Seligmann

  3. Department of Radiation, Institut Gustave-Roussy, 16bis, Avenue Paul-Vaillant-Couturier, F-94800, Villejuif, France

    Maurice Tubiana

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Belpomme, D. et al. (1978). Prognostic Factors and Treatment of Multiple Myeloma: Interest of a Cyclic Sequential Chemohormonotherapy Combining Cyclophosphamide, Melphalan, and Prednisone. In: Mathé, G., Seligmann, M., Tubiana, M. (eds) Lymphoid Neoplasias II. Recent Results in Cancer Research, vol 65. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81249-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81249-1_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81251-4

  • Online ISBN: 978-3-642-81249-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation